Abstract
Dysregulation of CpG-methylation is a common feature of many human cancers and tumour suppressor genes can be silenced by hypermethylation. Recently, 2 methyl-CpG-binding domain proteins have been linked to gene inactivation by their ability to recruit co-repressors and HDAC-activity to methylated gene promoters. Here, we have analysed mRNA expression of these genes, MeCP2 and MBD2, in a wide variety of primary human tumours. In solid tumours, expression levels of MBD2 (57/71) and MeCP2 (64/71) were significantly reduced in the majority of primary tumours as detected by quantitative real-time RT-PCR. Western blot analyses of MeCP2 in matched tumour–normal samples of patients with non-small-cell lung cancer (NSCLC) indicated reduced protein in a significant percentage of patients. In acute myelogenous leukaemia (n = 26), expression levels were only slightly reduced and did not differ between samples analysed at diagnosis or at the time of relapse. In early-stage NSCLC (n = 70) expression of MeCP2 and MBD2 was significantly lower in squamous cell carcinoma than in adenocarcinoma or large cell carcinoma (P = 0.03 and P = 0.01). To further elucidate the mechanisms of gene regulation, we analysed MeCP2 and MBD2 regulation during haematopoietic differentiation. No significant changes in MeCP2 or MBD2 expression were found when NB4 cells were differentiated toward granulocytes suggesting that neither differentiation nor cell cycle status were relevant for the reduced expression of these genes in human cancer. In conclusion, the significant loss of MeCP2 and MBD2 expression in human cancers suggests a potential role of this phenomenon in the development of solid human tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U and Zoghbi HY (1999) RETT syndrome is caused by mutations in X-linked MeCP2, encoding methyl-CpG-binding protein 2. Nat Genet 23: 185–188
Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R and Vidaud M (1999) Quantitation of Myc gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59: 2759–2765
Bird AP (1996) The relationship of DNA methylation to cancer. Cancer Surv 28: 87–101
Brandeis M, Ariel M and Cedar H (1993) Dynamics of DNA methylation during development. Bioessays 15: 709–713
Chih DY, Chumakov AM, Park DJ, Silla AG and Koeffler HP (1997) Modulation of mRNA expression of a novel human myeloid-selective CCAAT/enhancer binding protein gene (C/EBP epsilon). Blood 90: 2987–2994
Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB and Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59: 3352–3356
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O’Dorisio MS, Held WA, Cavenee WK and Plass C (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132–138
De Marzo AM, Marchi VL, Yang ES, Veeraswamy R, Lin X and Nelson WG (1999) Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res 59: 3855–3860
Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV and Laird PW (1999) CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 59: 2302–2306
Gaston K and Fried M (1995) CpG-methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes. Nucleic Acids Res 23: 901–909
Heid CA, Stevens J, Livak KJ and Williams PM (1996) Real time quantitative PCR. Genome Res 6: 986–994
Hendrich B and Bird A (1998) Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18: 6538–6547
Hendrich B, Abbott C, McQueen H, Chambers D, Cross S and Bird A (1999) Genomic structure and chromosomal mapping of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes. Mamm Genome 10: 906–912
Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J and Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187–191
Kanai Y, Ushijima S, Nakanishi Y and Hirohashi S (1999) Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem Biophys Res Commun 264: 962–966
Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E and Koeffler HP (1999) Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94: 1113–1120
Kudo S (1998) Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated. Mol Cell Biol 18: 5492–5499
Laird PW and Jaenisch R (1996) The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet 30: 441–464
Li E, Bestor TH and Jaenisch R (1992) Targeted Mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69: 915–926
Liang G, Salem CE, Yu MC, Nguyen HD, Gonzales FA, Nguyen TT, Nichols PW and Jones PA (1998) DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 53: 260–268
Müller-Tidow C, Metzger R, Kügler K, Diederichs S, Thomas M, Schneider P, Koeffler HP, Berdel WE and Serve H (2001) Cyclin E is the only CDK2 associated Cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res, in press
Müller C, Readhead C, Diederichs S, Idos G, Yang R, Tidow N, Serve H, Berdel WE and Koeffler HP (2000a) Methylation of the cyclin A1 promoter correlates with gene silencing in somatic cell lines, while tissue-specific expression of cyclin A1 is methylation independent. Mol Cell Biol 20: 3316–3329
Müller C, Yang R, Park DJ, Serve H, Berdel WE and Koeffler HP (2000b) The aberrant fusion proteins PML-RARa and PLZF-RARa contribute to the overexpression of Cyclin A1 in acute promyelocytic leukemia. Blood 96: 3894–3899
Nakamura M, Sugita K, Inukai T, Goi K, Iijima K, Tezuka T, Kojika S, Shiraishi K, Miyamoto N, Karakida N, Kagami K, T OK, Mori T and Nakazawa S (1999) p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation. Leukemia 13: 884–890
Nan X, Campoy FJ and Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88: 471–481
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN and Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386–389
Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D and Bird A (1999) MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23: 58–61
Ng HH, Jeppesen P and Bird A (2000) Active repression of methylated genes by the chromosomal protein MBD1. Mol Cell Biol 20: 1394–1406
Pradhan S, Talbot D, Sha M, Benner J, Hornstra L, Li E, Jaenisch R and Roberts RJ (1997) Baculovirus-mediated expression and characterization of the full length murine DNA methyltranferase. Nucleic Acid Res 25: 4666–4673
Santoli D, Francis MK, Matera L and Ferrero D (1983) Induction of proliferation and NK activity in human lymphocytes by mature myelomonocytic cells. J Immunol 131: 736–742
Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME and Rollins BJ (1995) Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 55: 6200–6209
Singal R and Ginder GD (1999) DNA Methylation. Blood 93: 4059–4070
Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH and Bang YJ (2000) Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma. Int J Cancer 87: 236–240
Swafford DS, Middleton SK, Palmisano WA, Nikula KJ, Tesfaigzi J, Baylin SB, Herman JG and Belinsky SA (1997) Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol 17: 1366–1374
Tate P, Skarnes W and Bird A (1996) The methyl-CpG binding protein MeCP2 is essential for embryonic development in the mouse. Nat Genet 12: 205–208
Walsh CP and Bestor TH (1999) Cytosine Methylation and mammalian development. Genes Dev 13: 26–34
Warnecke PM and Clark SJ (1999) DNA methylation profile of the mouse skeletal alpha-actin promoter during development and differentiation. Mol Cell Biol 19: 164–172
Xie S, Wang Z, Okano M, Nogami M, Li Y, He WW, Okumura K and Li E (1999) Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene 236: 87–95
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Müller-Tidow, C., Kügler, K., Diederichs, S. et al. Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. Br J Cancer 85, 1168–1174 (2001). https://doi.org/10.1054/bjoc.2001.2041
Received:
Revised:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.2041
Keywords
This article is cited by
-
MBD1, MBD2 and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers
Oncogene (2003)
-
MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status
British Journal of Cancer (2003)
-
Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs?
Oncogene (2002)
